Cargando…

Current Development Status of MEK Inhibitors

The current development status of mitogen-activated protein kinase kinase (MEK) inhibitors, including the preclinical data and clinical study progress, has been summarized in this review. Different MEK inhibitors, possessing specific physicochemical properties and bioactivity characteristics, may pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Ying, Tian, Hongqi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151813/ https://www.ncbi.nlm.nih.gov/pubmed/28954413 http://dx.doi.org/10.3390/molecules22101551

Ejemplares similares

Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor
por: Liu, Yahong, et al.
Publicado: (2023)

Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives
por: Welti, Michèle, et al.
Publicado: (2022)

Evaluation of the radiosensitizing effect of MEK inhibitor KZ-001 on non-small cell lung cancer cells in vitro
por: Huang, Gongchao, et al.
Publicado: (2023)

Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma
por: Zhao, Qian, et al.
Publicado: (2022)

MEK and the inhibitors: from bench to bedside
por: Akinleye, Akintunde, et al.
Publicado: (2013)

MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018)

Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands
por: Li, Xuejiao, et al.
Publicado: (2018)

A New Compound with Increased Antitumor Activity by Cotargeting MEK and Pim-1
por: Li, Yanan, et al.
Publicado: (2020)

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
por: Frémin, Christophe, et al.
Publicado: (2010)

ETS-targeted therapy: can it substitute for MEK inhibitors?
por: Tetsu, Osamu, et al.
Publicado: (2017)

MEK inhibitors as a chemotherapeutic intervention in multiple myeloma
por: Chang-Yew Leow, C, et al.
Publicado: (2013)

Trametinib: a MEK inhibitor for management of metastatic melanoma
por: Lugowska, Iwona, et al.
Publicado: (2015)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy
por: Tran, Khiem A, et al.
Publicado: (2015)

MEK inhibitors for the treatment of non-small cell lung cancer
por: Han, Jing, et al.
Publicado: (2021)

CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy
por: Turner, Elizabeth, et al.
Publicado: (2022)

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
por: Heinzerling, Lucie, et al.
Publicado: (2019)

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
por: Schreck, Karisa C., et al.
Publicado: (2019)

Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor
por: Küsters-Vandevelde, Heidi VN, et al.
Publicado: (2014)

MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions
por: Harder, Anja
Publicado: (2021)

Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
por: Ryu, Sunhyo, et al.
Publicado: (2017)

MEK genomics in development and disease
por: Bromberg-White, Jennifer L., et al.
Publicado: (2012)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
por: Reinhard, Raphael, et al.
Publicado: (2018)

In Vitro and In Vivo Efficacies of the EGFR/MEK/ERK Signaling Inhibitors in the Treatment of Alveolar Echinococcosis
por: Cheng, Zhe, et al.
Publicado: (2020)

Optimal Control Model of Tumor Treatment with Oncolytic Virus and MEK Inhibitor
por: Su, Yongmei, et al.
Publicado: (2016)

Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers
por: Kim, Bum Jun, et al.
Publicado: (2017)

PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2020)

Topical Delivery of Hedgehog Inhibitors: Current Status and Perspectives
por: Pedersen, Kristian Kåber, et al.
Publicado: (2022)

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status
por: Byron, Sara A, et al.
Publicado: (2012)

Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2
por: Yoshida, Takayuki, et al.
Publicado: (2012)

MEK Inhibitor U0126 Reverses Protection of Axons from Wallerian Degeneration Independently of MEK–ERK Signaling
por: Evans, Catherine, et al.
Publicado: (2013)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
por: Booth, Andrew E. C., et al.
Publicado: (2020)

Inhibition of glioblastoma dispersal by the MEK inhibitor PD0325901
por: Shannon, Stephen, et al.
Publicado: (2017)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis
por: Garutti, Mattia, et al.
Publicado: (2022)

Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy—Paradoxical ERK Activation and Beyond
por: Jung, Thomas, et al.
Publicado: (2021)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas
por: Armstrong, Amy E., et al.
Publicado: (2023)

Cellular and Molecular Mechanisms of MEK1 Inhibitor–Induced Cardiotoxicity
por: Beck, Tyler C., et al.
Publicado: (2022)

USP7 Inhibitors in Cancer Immunotherapy: Current Status and Perspective
por: Korenev, Georgiy, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mtkd966iga63fm228f7iras363